| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 21, 2005
From the Clinical Pharmacology Unit, and the Department of Medicine (M.M., A.C.), University of Cambridge, United Kingdom; and NephroUrology Unit, Great Ormond Street Hospital, London, United Kingdom (W.V.H.). * To whom correspondence should be addressed. E-mail: kmo22{at}medschl.cam.ac.uk.
Abstract--We identified a new kindred with the familial syndrome of hypertension and hyperkalemia (pseudohypoaldosteronism type II or Gordons syndrome) containing an affected father and son. Mutation analysis confirmed a single heterozygous G to C substitution within exon 7 (1690G>C) that causes a missense mutation within the acidic motif of WNK4 (564D>H). We confirmed the function of this novel mutation by coexpressing it in Xenopus oocytes with either the NaCl cotransporter (NCCT) or the inwardly rectifying K-channel (ROMK). Wild-type WNK4 inhibits 22Na+ flux in Xenopus oocytes expressing NCCT by
Revised on April 13, 2005
A New Kindred With Pseudohypoaldosteronism Type II and a Novel Mutation (564D>H) in the Acidic Motif of the WNK4 Gene
Amir P. Golbang;
90% (P<0.001), whereas the 564D>H mutant had no significantly inhibitory effect on flux through NCCT. In oocytes expressing ROMK, wild-type WNK4 produced >50% inhibition of steady-state current through ROMK at a +20-mV holding potential (P<0.001). The 564D>H mutant produced further inhibition with steady-state currents to some 60% to 70% of those seen with the wild-type WNK4. Using fluorescent-tagged NCCT (enhanced cyan fluorescent protein-NCCT) and ROMK (enhanced green fluorescent protein-ROMK) to quantify the expression of the proteins in the oocyte membrane, it appears that the functional effects of the 564D>H mutation can be explained by alteration in the surface expression of NCCT and ROMK. Compared with wild-type WNK4, WNK4 564D>H causes increased cell surface expression of NCCT but reduced expression of ROMK. This work confirms that the novel missense mutation in WNK4, 564D>H, is functionally active and highlights further how switching charge on a single residue in the acid motif of WNK4 affects its interaction with the thiazide-sensitive target NCCT and the potassium channel ROMK.
This article has been cited by other articles:
![]() |
Z. Zhang, X. Xu, Y. Zhang, J. Zhou, Z. Yu, and C. He LINGO-1 Interacts with WNK1 to Regulate Nogo-induced Inhibition of Neurite Extension J. Biol. Chem., June 5, 2009; 284(23): 15717 - 15728. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Glover, A. M. Zuber, and K. M. O'Shaughnessy Renal and Brain Isoforms of WNK3 Have Opposite Effects on NCCT Expression J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1314 - 1322. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhang, T. Na, and J.-B. Peng WNK3 positively regulates epithelial calcium channels TRPV5 and TRPV6 via a kinase-dependent pathway Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1472 - F1484. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Richardson and D. R. Alessi The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway J. Cell Sci., October 15, 2008; 121(20): 3293 - 3304. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. McCormick, C.-L. Yang, and D. H. Ellison WNK Kinases and Renal Sodium Transport in Health and Disease: An Integrated View Hypertension, March 1, 2008; 51(3): 588 - 596. [Full Text] [PDF] |
||||
![]() |
J.-B. Peng and D. G. Warnock WNK4-mediated regulation of renal ion transport proteins Am J Physiol Renal Physiol, October 1, 2007; 293(4): F961 - F973. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Golbang, G. Cope, A. Hamad, M. Murthy, C.-H. Liu, A. W. Cuthbert, and K. M. O'Shaughnessy Regulation of the expression of the Na/Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved Am J Physiol Renal Physiol, December 1, 2006; 291(6): F1369 - F1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Kahle, J. Rinehart, A. Ring, I. Gimenez, G. Gamba, S. C. Hebert, and R. P. Lifton WNK Protein Kinases Modulate Cellular Cl- Flux by Altering the Phosphorylation State of the Na-K-Cl and K-Cl Cotransporters. Physiology, October 1, 2006; 21: 326 - 335. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cope, M. Murthy, A. P. Golbang, A. Hamad, C.-H. Liu, A. W. Cuthbert, and K. M. O'Shaughnessy WNK1 Affects Surface Expression of the ROMK Potassium Channel Independent of WNK4 J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1867 - 1874. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Leng, K. T. Kahle, J. Rinehart, G. G. MacGregor, F. H. Wilson, C. M. Canessa, R. P. Lifton, and S. C. Hebert WNK3, a kinase related to genes mutated in hereditary hypertension with hyperkalaemia, regulates the K+ channel ROMK1 (Kir1.1) J. Physiol., March 1, 2006; 571(2): 275 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hadchouel, C. Delaloy, S. Faure, J.-M. Achard, and X. Jeunemaitre Familial Hyperkalemic Hypertension J. Am. Soc. Nephrol., January 1, 2006; 17(1): 208 - 217. [Full Text] [PDF] |
||||
![]() |
H. Zhang and J. A. Staessen Association of Blood Pressure With Genetic Variation in WNK Kinases in a White European Population Circulation, November 29, 2005; 112(22): 3371 - 3372. [Full Text] [PDF] |
||||
![]() |
C. Delaloy, J. Hadchouel, and X. Jeunemaitre With-No-Lysine Kinases: The Discovery of a New Pathway in Hypertension Using Human Genetic Studies Hypertension, August 1, 2005; 46(2): 263 - 264. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |